Educational Case: Glucose-6-phosphate dehydrogenase (G6PD) deficiency anemia Authors: Katie Bussing, Nicholas Brehl, Ashley Inman, Darrell Davidson Published: 2026 The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see https://doi.org/10.1016/j.acpath.2023.100086.1 The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see https://doi.org/10.1016/j.acpath.2023.100086.1 Primary objective Objective HRC1.5: Anemias of Red Cell Destruction. Explain the mechanisms by which anemia is produced on the basis of shortened red cell survival, distinguishing between intrinsic and extrinsic causes of red cell destruction. Competency 2: Organ System Pathology; Topic Hematopathology: Red Cell Disorders (HRC); Learning Goal 1: Anemia. Secondary objective Objective GM1.2: Inheritance Patterns. Compare and contrast the inheritance patterns of different types of Mendelian disorders and give examples of each type of pattern. Competency 1: Disease Mechanisms and Processes; Topic: Genetic Mechanisms (GM); Learning Goal 1: Genetic Mechanisms of Developmental and Functional Abnormalities. Patient presentation A 5-year-old boy comes to the emergency department (ED) with his parents for progressively yellowing eyes over the past 24 hours. He is less active than usual, complains of belly pain, and has a mild fever. The parents did notice the child had darker urine this morning, although the stool is normal in color. The boy has eaten no new foods nor recently traveled from home. Five days earlier, he was assessed in the ED for bacterial pneumonia with mild symptoms and treated with amoxicillin. The parents report that he has taken all doses of the antibiotic on schedule, and the antibiotic treatment will be completed in two more days. He was sent home after the ED visit and had been doing well until the last 24 hours. There are no chronic health issues or history of transfusions. His mother had an uncomplicated pregnancy and recalls no history of neonatal hyperbilirubinemia. The parents report no previous episodes of jaundice. He has met all developmental milestones and has appropriate growth for his age. He has received all age-appropriate vaccinations. The maternal grandfather has G6PD (glucose-6-phosphate dehydrogenase) deficiency, and the paternal grandfather has sickle cell disease. The patient has a healthy 2-year-old sister. They report no other personal or family history of jaundice, easy bleeding, or blood disorders. The patient has a heart rate of 130 bpm, mild tachypnea, and a temperature of 100.6 F. His physical exam shows scleral icterus, pale conjunctivae, and jaundice of the head and upper chest. There is mild splenomegaly with no localizing tenderness in the abdomen. Specifically, there is no tenderness at McBurney's point, and Murphy's sign is negative. Diagnostic findings, Part 1 The urine dipstick is positive for hemoglobin, urobilinogen, and bilirubin. Table 1 shows the initial laboratory testing for the patient with reference values.2,3Table 1Laboratory testing.Table 1Patient ValuesReference RangeRBC count3.03 L4.00–5.10 (x 1012/L)Hematocrit24.2% L34–40%Hemoglobin8.0 L11.4–14.3 (g/dL)MCV80.077.2–89.5 (fL)MCHC33.032.0–36.0 (g/dL)RDW12.611.3–13.4 (%)Platelet count245187–445 (x 109/L)WBC count14.0 H4.4–12.9 (x 109/L)Reticulocyte count4.5 H0.5–1.5 (%)Total bilirubin6.5 H<1.0 (mg/dL)Direct bilirubin0.7 H0.0–0.3 (mg/dL)Haptoglobin12 L30–191 (mg/dL)Lactate dehydrogenase542 H145-345 (U/L)BUN77–20 (mg/dL)ALT107–55 (U/L)AST608–60 (U/L)Alkaline phosphatase200142-335 (U/L)GGT15<21 (U/L)Abbreviations: MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; WBC, white blood cell; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase. Table 1Laboratory testing.Table 1Patient ValuesReference RangeRBC count3.03 L4.00–5.10 (x 1012/L)Hematocrit24.2% L34–40%Hemoglobin8.0 L11.4–14.3 (g/dL)MCV80.077.2–89.5 (fL)MCHC33.032.0–36.0 (g/dL)RDW12.611.3–13.4 (%)Platelet count245187–445 (x 109/L)WBC count14.0 H4.4–12.9 (x 109/L)Reticulocyte count4.5 H0.5–1.5 (%)Total bilirubin6.5 H<1.0 (mg/dL)Direct bilirubin0.7 H0.0–0.3 (mg/dL)Haptoglobin12 L30–191 (mg/dL)Lactate dehydrogenase542 H145-345 (U/L)BUN77–20 (mg/dL)ALT107–55 (U/L)AST608–60 (U/L)Alkaline phosphatase200142-335 (U/L)GGT15<21 (U/L)Abbreviations: MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; WBC, white blood cell; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase. Laboratory testing. Abbreviations: MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; WBC, white blood cell; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase. Questions/discussion points, Part 1 What are some causes of jaundice in a pediatric patient? We confirmed that the child has hyperbilirubinemia by the dark urine, positive for bilirubin and urobilinogen. The darkening of the urine is also partly due to hematin, either from erythrocytes (hematuria) or from free hemoglobin (hemoglobinuria). The boy's jaundice may have pre-hepatic, hepatic, or post-hepatic causes. His liver enzymes are not elevated, so hepatitis, hepatotoxins, or biliary obstruction are unlikely causes for his icterus. The bilirubin in circulation includes unconjugated (indirect) bilirubin and conjugated (direct) bilirubin. Splenic macrophages process erythrocyte heme into biliverdin and unconjugated bilirubin, which is processed into conjugated bilirubin in the liver. Direct bilirubin is the conjugated bilirubin fraction reacting rapidly in an aqueous solution with diazo reagents. Indirect bilirubin is calculated by subtracting direct bilirubin from total bilirubin. Fractionated bilirubin helps differentiate prehepatic, extrahepatic, and obstructive jaundice. Hepatic and post-hepatic etiologies have higher proportions of conjugated bilirubin, and different liver enzyme profiles distinguish between the two categories. Elevations of liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) signal hepatocyte injury, whereas alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) indicate biliary obstruction. Fig. 1 shows a schematic for evaluating children with jaundice.4 There is unconjugated hyperbilirubinemia if the conjugated bilirubin (direct) fraction is less than 15% of the total bilirubin. The boy's direct bilirubin is 11%, so he has unconjugated hyperbilirubinemia. Pre-hepatic etiologies include overproduction of bilirubin due to hemolysis or ineffective erythropoiesis, which shortens erythrocyte survival. Some congenital defects of bilirubin processing in the liver may also lead to the accumulation of unconjugated bilirubin.Fig. 1A schematic for causes of jaundice in a pediatric patient. In a patient with hyperbilirubinemia, the difference between total bilirubin and the conjugated bilirubin fraction is the unconjugated fraction. Due to hemolysis, unconjugated bilirubin rapidly increases from hemoglobin breakdown in the reticuloendothelial system. Alternatively, a patient may accumulate indirect bilirubin due to an innocuous inherited deficiency in the hepatocyte bilirubin conjugation pathway, Gilbert's syndrome. Excess conjugated bilirubin usually indicates hepatic injury or biliary obstruction. A schematic for causes of jaundice in a pediatric patient. In a patient with hyperbilirubinemia, the difference between total bilirubin and the conjugated bilirubin fraction is the unconjugated fraction. Due to hemolysis, unconjugated bilirubin rapidly increases from hemoglobin breakdown in the reticuloendothelial system. Alternatively, a patient may accumulate indirect bilirubin due to an innocuous inherited deficiency in the hepatocyte bilirubin conjugation pathway, Gilbert's syndrome. Excess conjugated bilirubin usually indicates hepatic injury or biliary obstruction. The patient's normal brown stool color suggests that the liver is conjugating and excreting bilirubin, whereas jaundice implies that the liver's conjugating capacity is overwhelmed. Urobilinogen detected by the urine dipstick is a colorless metabolite of bilirubin made by gastrointestinal bacteria and reabsorbed into the circulation. The boy's clinical presentation and laboratory findings indicate jaundice due to hemolysis or shortened erythrocyte lifespan. Normal red blood cells (RBCs) survive in circulation for 120 days (95% CI 110–122 days). Anemia results when the lifespan of RBCs falls below the bone marrow's capacity to maintain homeostasis by increasing erythropoiesis. Premature destruction of RBCs, shortening the lifespan, releases hemoglobin molecules. Macrophage processing of hemoglobin recycles iron, hydrolyzes globin into amino acids, and opens the iron-binding porphyrin ring. Heme oxygenase (HMOX1) in splenic macrophages opens the porphyrin ring, releasing carbon monoxide and the green tetrapyrrole pigment, biliverdin. Bruises turn green because of heme oxygenase (HMOX2) in all tissues. Biliverdin reductase (BLVRA, BLVRB), also expressed in all tissues, converts biliverdin to bilirubin, a lipophilic yellow molecule. Bilirubin bound to plasma albumin travels to the liver, where hepatocytes make it water-soluble by conjugating it with glucuronic acid for excretion in bile. Unconjugated bilirubin accumulates in the circulation when production of bilirubin exceeds hepatic conjugation capacity. Unconjugated hyperbilirubinemia is a consequence of excessive hemolysis. What is the differential diagnosis for unconjugated hyperbilirubinemia in a pediatric patient? Causes for unconjugated hyperbilirubinemia in children often differ from those in neonates or adults. Fetal hemoglobin turnover is rapid in neonates, causing transient jaundice in many infants. In adults, acquired conditions are frequently the cause of unconjugated hyperbilirubinemia. When the initial laboratory values and the clinical history fail to explain a low direct bilirubin fraction in a jaundiced patient, then a peripheral blood smear is an inexpensive and informative next step, often requiring no additional blood draw (Fig. 2).5 Gilbert's syndrome, a heritable liver enzyme abnormality in 3%–7% of Americans, causes asymptomatic hyperbilirubinemia and mild jaundice but decreased coronary artery disease and reduced all-cause mortality. An episode of jaundice brought on by stress, exercise, or infection in late adolescence or early adulthood is the most common occasion for the diagnosis of Gilbert's syndrome. Crigler-Najjar syndrome is a more severe liver glucuronidation enzyme deficiency that causes kernicterus and death in infants, except for the Type II patients with partial enzyme deficiency, who can be treated by liver transplantation.Fig. 2Peripheral smear value for hemolytic anemia diagnosis. The morphology of erythrocytes in a peripheral blood smear yields valuable diagnostic clues to the etiology of hemolytic anemia. Although target cells and spherocytes are somewhat nonspecific, they are more common in thalassemia and hereditary spherocytosis than in immune-mediated hemolytic anemia. Microangiopathic hemolytic anemia (MAHA) results from endothelial injury, intravascular thrombosis, or mechanical shearing of erythrocytes. Most cases are caused by hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), or disseminated intravascular coagulopathy (DIC). Peripheral smear value for hemolytic anemia diagnosis. The morphology of erythrocytes in a peripheral blood smear yields valuable diagnostic clues to the etiology of hemolytic anemia. Although target cells and spherocytes are somewhat nonspecific, they are more common in thalassemia and hereditary spherocytosis than in immune-mediated hemolytic anemia. Microangiopathic hemolytic anemia (MAHA) results from endothelial injury, intravascular thrombosis, or mechanical shearing of erythrocytes. Most cases are caused by hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), or disseminated intravascular coagulopathy (DIC). In children, indirect hyperbilirubinemia is usually caused by hemolysis. Splenomegaly is a common finding in extravascular hemolysis, driven by splenic macrophage activation. Extravascular hemolysis results from either intra-corpuscular (intrinsic) or extra-corpuscular (extrinsic) defects. Intrinsic defects in red blood cells include abnormalities in enzymes, hemoglobin, and cell membranes. In some regions, malaria parasitemia can also cause hemolysis due to intracorpuscular infection. Extra-corpuscular hemolysis in children may be autoimmune, drug-induced, or microangiopathic. A hallmark of microangiopathic anemia is the presence of schistocytes in the peripheral blood smear. Patients may show signs of intravascular (hemoglobinemia) and extravascular (splenomegaly) hemolysis during acute exacerbations of chronic hemolytic anemia. How do the laboratory results narrow the differential diagnosis? The low conjugated bilirubin fraction indicates rapid release of porphyrin from degraded hemoglobin or impaired bilirubin conjugation. The hepatobiliary enzymes, AST, ALT, and GGT, are within the normal range. Therefore, a diagnosis of liver impairment, such as infectious hepatitis or drug hepatotoxicity, is unlikely. In addition to unconjugated hyperbilirubinemia and normocytic anemia, other lab abnormalities point toward hemolysis in this case. During hemolysis, lactate dehydrogenase (LDH) enters the blood plasma, causing increased LDH. Haptoglobin binds free hemoglobin from disrupted erythrocytes, forming a complex that is rapidly removed from circulation by the spleen. The decreased haptoglobin and increased lactate dehydrogenase are consistent with acute intravascular hemolysis. The reticulocyte count increases as the bone marrow strives to replace the destroyed erythrocytes. This peripheral blood value increases in 3–5 days after an acute blood loss. The elevated reticulocyte count indicates a shortened red cell lifespan or bleeding with a normal compensatory erythropoietic response. Therefore, the patient has unconjugated hyperbilirubinemia due to erythrocyte hemoglobin release because of hemolysis exceeding the liver's conjugating capacity. The hemolytic episode is superimposed on chronic hemolytic anemia. What is the differential diagnosis for hemolytic anemia? The causes of hemolytic anemia are either extrinsic to or intrinsic to the red blood cells.6 Extrinsic factors causing hemolytic anemia include immune etiologies, such as autoimmune or drug-induced hemolysis, and microangiopathic hemolytic anemias, such as hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP). Hemolytic anemias caused by intrinsic erythrocyte defects include most inherited anemias, such as hereditary spherocytosis, thalassemia, sickle cell disease, and G6PD deficiency. Hemolysis by mechanical damage to red blood cells occurs in the intravascular space, releasing free hemoglobin into the circulation. Damaged or senescent erythrocytes are phagocytosed by reticuloendothelial macrophages, predominantly in the spleen, resulting in splenomegaly. Table 2 summarizes common intrinsic and extrinsic, intravascular and extravascular red cell destruction mechanisms.Table 2Red cell destruction mechanisms.Table 2ConditionAgencyPrimary MechanismLocation of HemolysisKey Smear FindingDiagnostic TestMicroangiopathic (MAHA)ExtrinsicMechanical shearingIntravascularSchistocytes (fragments)Smear & Coagulation profileAutoimmune (Warm)ExtrinsicIgG-mediated opsonizationExtravascular (Spleen)SpherocytesPositive Direct Coombs (DAT)Hereditary SpherocytosisIntrinsicMembrane protein defect (ankyrin/spectrin)Extravascular (Spleen)SpherocytesOsmotic fragility/EMA bindingThalassemiaIntrinsicGlobin gene mutation (α or β) causes chain unit imbalanceExtravascular (Spleen)Anisopoikilo-, Reticulo-cytosis, (non-specific)Hb electrophoresisSickle cell anemiaIntrinsicHemoglobin S polymerization under low oxygenExtravascularSickle cells & Target cellsHb ElectrophoresisG6PD DeficiencyIntrinsicOxidative stress causes hemoglobin denaturationBoth (Intra & Extra)Heinz bodies & bite cellsG6PD enzyme assay (post-flare) Table 2Red cell destruction mechanisms.Table 2ConditionAgencyPrimary MechanismLocation of HemolysisKey Smear FindingDiagnostic TestMicroangiopathic (MAHA)ExtrinsicMechanical shearingIntravascularSchistocytes (fragments)Smear & Coagulation profileAutoimmune (Warm)ExtrinsicIgG-mediated opsonizationExtravascular (Spleen)SpherocytesPositive Direct Coombs (DAT)Hereditary SpherocytosisIntrinsicMembrane protein defect (ankyrin/spectrin)Extravascular (Spleen)SpherocytesOsmotic fragility/EMA bindingThalassemiaIntrinsicGlobin gene mutation (α or β) causes chain unit imbalanceExtravascular (Spleen)Anisopoikilo-, Reticulo-cytosis, (non-specific)Hb electrophoresisSickle cell anemiaIntrinsicHemoglobin S polymerization under low oxygenExtravascularSickle cells & Target cellsHb ElectrophoresisG6PD DeficiencyIntrinsicOxidative stress causes hemoglobin denaturationBoth (Intra & Extra)Heinz bodies & bite cellsG6PD enzyme assay (post-flare) Red cell destruction mechanisms. Consider the epidemiology and inheritance patterns of common hereditary anemias. How might this narrow the differential diagnosis in this patient? Hereditary spherocytosis may affect up to one in every 2000 people.7 It is inherited primarily in an autosomal dominant pattern. Therefore, one would expect to see every generation affected in a family, which is not the case for this patient. Autosomal dominant inheritance means that a single copy of the mutant gene may cause the disorder. Thus, if either parent is affected, 50% of the offspring will inherit the mutant allele, regardless of sex. Thalassemia is a common autosomal recessive hemoglobinopathy, with up to 5% of the world's population being disease carriers.8 Autosomal recessive inheritance indicates that both sexes are affected equally and that both parents must be carriers of the recessive trait. There is no family history of thalassemia, and neither parent has a history of anemia consistent with thalassemia minor. Sickle cell disease affects about 100,000 people in the United States.9 The disease results from a mutation in the sixth position of the beta hemoglobin chain, substituting a hydrophobic valine amino acid for glutamic acid. The altered hemoglobin polymerizes into rodlike inclusions when fully deoxygenated. The inclusions distort affected erythrocytes into a sickle shape and increase the blood viscosity. A single copy of the mutated gene is present in up to 1 in 12 individuals.10 Carriers of the trait are asymptomatic except when scuba diving, mountain climbing, or severely dehydrated. Sickle cell disease, characterized by severe pain crises and anemia that typically begin in infancy, is an autosomal recessive disorder. This patient's paternal grandfather has sickle cell disease, so the father carries the trait. Even so, there is only a 50% chance that he passed the gene to the boy, and a smaller chance that the mother is also a carrier. G6PD deficiency is an X-linked recessive disorder affecting more than 400 million people worldwide, making it the most common human enzyme deficiency known. In some populations, up to 1 in every 10 individuals has the disease.11 The disease results from an enzyme deficiency, shortening the red cell lifespan and rendering the cells susceptible to high redox potential chemicals in the circulation. The patient's mother must be a carrier of the mutation because the patient's maternal grandfather had this X-linked disease. The boy's other sex chromosome is Y, so he has at least a 50% chance of inheriting the X-linked disease from his mother. Diagnostic findings, Part 2 Fig. 3D shows a photomicrograph of the boy's peripheral blood smear.Fig. 3Peripheral smear evaluation of hemolytic anemia for the pediatric patient. (A) Hereditary spherocytosis shows abundant microcytic spherocytes (black arrows) and scattered normocytic spherocytes (red arrow). The latter helps rule out membrane damage in other hemolytic anemias, such as microangiopathic hemolytic anemia (MAHA, shown in B), and in other conditions with red cell injury. (B) MAHA (hemolytic-uremic syndrome, HUS in this case) shows schistocytes (black arrows) and polychromatic macrocytes (red arrows). (C) Sickle cell disease shows sickle cells (black arrows), codocytes ("target cells," red arrows), Howell-Jolly bodies (green arrow), and nucleated erythrocytes (blue arrows). (D) G6PD deficiency shows degmacytes ("bite cells," black arrows) and blister cells (red arrows). A small lymphocyte nucleus in each image is approximately the size of a normocyte. (x1000, high power with oil immersion). Peripheral smear evaluation of hemolytic anemia for the pediatric patient. (A) Hereditary spherocytosis shows abundant microcytic spherocytes (black arrows) and scattered normocytic spherocytes (red arrow). The latter helps rule out membrane damage in other hemolytic anemias, such as microangiopathic hemolytic anemia (MAHA, shown in B), and in other conditions with red cell injury. (B) MAHA (hemolytic-uremic syndrome, HUS in this case) shows schistocytes (black arrows) and polychromatic macrocytes (red arrows). (C) Sickle cell disease shows sickle cells (black arrows), codocytes ("target cells," red arrows), Howell-Jolly bodies (green arrow), and nucleated erythrocytes (blue arrows). (D) G6PD deficiency shows degmacytes ("bite cells," black arrows) and blister cells (red arrows). A small lymphocyte nucleus in each image is approximately the size of a normocyte. (x1000, high power with oil immersion). Questions/discussion points, Part 2 Describe the findings of the boy's peripheral blood smear The peripheral blood smear is a valuable tool for diagnosing hemolytic anemias, as many cases exhibit abnormal erythrocyte morphology. Erythrocyte morphologies associated with hemolytic anemia are shown in Fig. 3.12 Bite cells (degmacytes) result from splenic macrophages removing particles of denatured hemoglobin called Heinz bodies. Blister cells occur when the cell surface membrane reseals after injury in the spleen. Describe the biochemistry, hemolysis triggers, and epidemiology of this disorder The most likely diagnosis is G6PD deficiency. This enzyme in the pentose phosphate pathway is the main generator of NADPH.13 Lacking mitochondria and nuclei, erythrocytes have no alternate source of this critical oxidative damage-reversing metabolite. NADPH protects against oxidative stress by donating reductive potential to glutathione. Most patients with G6PD deficiency are asymptomatic until exposure to an oxidative stress trigger. Despite frequent reports of hemolysis induced by fava beans or medication, infection triggers most acute hemolytic episodes in patients with G6PD deficiency. Common infectious causes include pneumonia, hepatitis A and B, and cytomegalovirus.13 Many drugs commonly prescribed may cause a hemolytic crisis, including acetaminophen, aspirin, chloramphenicol, vitamin C, bupivacaine, glipizide, mefloquine, nitric oxide, primaquine, and most sulfa drugs. The Italian G6PD Deficiency Association has provided a list of 143 drugs with relative hemolysis risk.14 G6PD deficiency prevalence is less than 5% in the Americas but may exceed 20% in parts of western and southern Africa. It is also greater than 10% in many parts of Asia. Areas of high prevalence overlap significantly with regions having endemic malaria. Primaquine is, therefore, a less useful treatment for Plasmodium ovale and P. vivax in these regions. Some investigators have proposed that G6PD deficiency may confer resistance to P. falciparum infection, like the antimalarial protection conferred by other hemoglobinopathies. How does G6PD deficiency cause hemolysis? The common denominator amongst these triggers is oxidative stress. Once the erythrocyte's supply of reduced glutathione is depleted, oxidants damage the erythrocytes, accumulating membrane polypeptide aggregates and denatured hemoglobin aggregates (Heinz bodies) within the cytoplasm.13 Erythrocytes become rigid and prone to destruction by splenic macrophages, causing extravascular acute hemolytic anemia, the most common clinical manifestation of the disease. G6PD deficiency can also manifest as neonatal hyperbilirubinemia, although the pathophysiology is less understood.15 Laboratory testing in G6PD deficiency anemia shows a negative direct antiglobulin test (direct Coomb's test). The peripheral smear shows degmacytes ("bite cells"), which are red blood cells with a semicircular indent from the removal of Heinz bodies by splenic macrophages. A supravital stain is needed to visualize the Heinz bodies, but the routine Romanowsky-stained smear reveals degmacytes (Fig. 3A).16 How is suspected G6PD deficiency diagnosed and treated? For screening, semiquantitative fluorescent spot testing is fast and inexpensive.17 A drop of whole blood is incubated with glucose-6-phosphate and NADP+. Any G6PD enzyme present in the blood produces fluorescent NADPH, which is detectable in the dried spot under ultraviolet light. Normal G6PD activity produces bright fluorescence, whereas enzyme deficiency results in dim or absent fluorescence. For confirmatory testing, the gold standard is the quantitative spectrophotometric measurement of enzyme activity via NADPH formation.18 PCR is useful to detect known mutations in the G6PD gene, but this is more costly and time-consuming. Spectrophotometric testing or PCR may benefit female heterozygous patients or patients with mutations causing borderline enzyme activity. Point-of-care testing is also an emerging option, although its current sensitivity and specificity limit its utility.19 Treatment for acute clinical manifestations of the disease is no different from typical management for unconjugated hyperbilirubinemia. These include phototherapy for neonatal hemolysis and supportive treatments for youth and adults. These may include oxygen therapy, transfusion, hospitalization, and adequate hydration. Patients with acute hemolytic anemia may require blood transfusions if hemoglobin falls below 8 g/dL and clinical signs indicate inadequate oxygenation of critical organs. If applicable, another consideration is the removal of the offending agent, such as a medication. Long-term disease management involves avoiding foods and medications that trigger oxidative stress.14 When should this patient receive testing for G6PD deficiency? When a G6PD-deficient patient has an acute hemolytic episode, the erythrocytes with inferior G6PD function tend to hemolyze first, leaving only the erythrocytes with more appropriate G6PD function. Diagnostic testing that measures enzyme activity may give a falsely normal result at that time. Therefore, diagnostic testing should occur several months after an acute hemolytic episode, when a new population of erythrocytes has entered the circulation.20 Describe the G6PD variants, their classification, and their clinical relevance Over 400 mutations in the G6PD gene have been identified.21 The two most common variants are G6PD Mediterranean, typical in people of Mediterranean descent, and G6PD A-, common in people of African descent. Some characteristics of the variants have been described. For example, the Mediterranean G6PD variant is more likely to present with severe neonatal hyperbilirubinemia, whereas the G6PD A-variant is less sensitive to fava bean-induced oxidative stress.22 In 1985, the World Health Organization published classifications of G6PD deficiency that are still used today (Table 3).23 In this system, variants of G6PD deficiency have been categorized as Class I–V based on the percentage of functional G6PD activity. For example, the G6PD A-variant is a class III variant with 10–60% enzyme activity. This classification system is useful to assess each variant's risk of hemolysis in the patient.23 For long-term management, G6PD gene sequencing and CYP450 pharmacogenomic testing may provide information about specific drugs and foods to avoid.18Table 3Risk of hemolysis based on the WHO G6PD deficiency classification, 1985.23Table 3ClassEnzyme activity (% of normal)Clinical symptomsCommon clinical and genetic featuresI<10%Chronic non-spherocytic hemolytic anemiaSevere hemolytic crisis on oxidant exposureII<10%Intermittent severe acute hemolysisG6PD Mediterranean (Gd Med)III10–60%Intermittent moderate acute hemolysisG6PD African (Gd A-)IV60–150%No hemolytic riskIncludes G6PD wild typeV>150%No hemolytic riskNo clinical significance, elevated in normal term neonates Table 3Risk of hemolysis based on the WHO G6PD deficiency classification, 1985.23Table 3ClassEnzyme activity (% of normal)Clinical symptomsCommon clinical and genetic featuresI<10%Chronic non-spherocytic hemolytic anemiaSevere hemolytic crisis on oxidant exposureII<10%Intermittent severe acute hemolysisG6PD Mediterranean (Gd Med)III10–60%Intermittent moderate acute hemolysisG6PD African (Gd A-)IV60–150%No hemolytic riskIncludes G6PD wild typeV>150%No hemolytic riskNo clinical significance, elevated in normal term neonates Risk of hemolysis based on the WHO G6PD deficiency classification, 1985.23 Discuss the other common inherited anemias with respect to pathophysiology, clinical presentation, and diagnosis Hereditary Spherocytosis. A defect in erythrocyte membrane proteins, such as ankyrin and spectrin, causes hereditary spherocytosis.24 These defects cause the erythrocyte to adopt a spherical shape instead of the normal biconcave disc. Spherocytes have greater difficulty traversing the spleen and are phagocytosed by splenic macrophages, resulting in both splenomegaly and hemolytic anemia. Patients may present at various ages and with illnesses of varying severity. Neonatal hyperbilirubinemia is common, but patients may also present later with asymptomatic splenomegaly or anemia, pigmented gallstones, or a hemolytic crisis during infection.16 Laboratory results showing hemolytic anemia and an elevated mean corpuscular hemoglobin concentration are especially suggestive of the disease. The peripheral smear shows spherocytes, although they are not exclusive to this disease (Fig. 3A). Spherocytes are also present in other conditions, such as autoimmune hemolytic anemia and red cell injury (Fig. 3B). The diagnosis is confirmed by specialized tests such as osmotic fragility or eosin-5-maleimide flow cytometry.24 Fluorescence intensity of this membrane-intercalating marker decreases when there is a mutation of the structural membrane proteins regulating red cell elasticity and deformability, usually ankyrin and spectrin. Thalassemia. Thalassemia is caused by mutations in the alpha or beta globin gene that reduce their production or functional activity.8 There are four alpha globin and two beta globin genes, and the number of defective genes a patient carries determines the clinical presentation, ranging from asymptomatic to in utero death.25 However, many patients have chronic anemia that may require transfusions. Acute hemolytic crisis can occur with this disease. Crisis triggers include infection, fever, oxidative stress, and pregnancy.25 In terms of laboratory findings, thalassemia is unique, as it causes not only hemolysis but also ineffective erythropoiesis. Therefore, patients have evidence of hemolysis, microcytic anemia, and a mildly elevated reticulocyte count. The peripheral smear shows microcytic erythrocytes and target cells, but these findings are also signs of iron-deficiency anemia and chronic liver disease. The diagnosis is confirmed with genetic testing, and hemoglobin electrophoresis or high-performance liquid chromatography (HPLC).26 Sickle Cell Disease. Due to a point mutation in the beta-globin gene, hemoglobin tends to polymerize, particularly under deoxygenated conditions in capillary beds. This polymerization distorts the erythrocytes into a sickle shape. These altered red blood cells behave differently from normal erythrocytes. They tend to initiate inflammatory cascades, hemolyze, bind to the endothelial wall, and become trapped in narrow capillaries.9 Symptoms emerge as early as 6 months of age when adult hemoglobin replaces fetal hemoglobin.26 In terms of anemia, sickle cell patients have chronic hemolytic anemia, which can worsen acutely. Acute hemolytic episodes are commonly due to hyperhemolysis during infection, although many other causes are possible. In children, acute worsening of anemia may accompany splenic sequestration, in which sickled cells become trapped in the spleen, causing sudden enlargement and pain. Reticulocytosis and thrombocytopenia are often present. After age 5, splenic sequestration does not occur, as the spleen has become small and nonfunctional (autosplenectomy) due to repeated microinfarctions.26 Besides anemia, another clinical manifestation of the disease is a vaso-occlusive crisis, a painful occlusion of the microvascular beds by the rigid, sickle-shaped erythrocytes.9 The occlusions can occur anywhere, such as in long bones or the chest, but in children, they tend to occur in the fingers, causing dactylitis. In terms of diagnosis, a peripheral blood smear shows sickle cells in about 90% of cases (Fig. 3C). Howell-Jolly bodies, nuclear remnants, may also be seen and are indicative of a nonfunctional spleen. A definitive diagnosis is made with hemoglobin electrophoresis or HPLC. What are the screening guidelines for common inherited anemias? In the United States, G6PD deficiency is not included in the recommended uniform screening panel and is not routinely performed in most states.27 The American Academy of Pediatrics does recommend screening in some instances of neonatal jaundice. Internationally, screening is infrequent, despite the World Health Organization recommending it in populations with disease prevalence greater than 5%. Africa and the Middle East have the lowest screening rates despite having the highest disease prevalence.28 Sickle cell disease screening for all newborns is common in many countries, including the United States, the United Kingdom, Spain, and Germany.28 However, Africa, the area with the highest rates of sickle cell disease, has no universal screening policy in any country. Although the core recommended newborn screening panel in the United States does not include thalassemia, many states perform some testing.29 There is no screening test for hereditary spherocytosis, which results from various gene mutations.30 Evaluation of red blood cell indices may identify patients with spherocytosis, and an elevated MCHC >36.5 g/dL is highly suggestive.31 How should this patient be treated? The patient's amoxicillin should be discontinued, and he should be advised to return to the ED if his fever or cough increases. There should be no transfusion because he has no shortness of breath, dizziness, or congestive heart failure, and the hemoglobin is not below 8 g/dL. He and his parents should be instructed to avoid fava beans and to inform prescribers that he should not receive amoxicillin, sulfonamides, primaquine, or fluoroquinolones.14 Teaching points •Mechanisms of shortened red cell survival include: (intravascular destruction): mechanical shearing for microangiopathic hemolytic anemia; (extravascular destruction): IgA-mediated opsonization for autoimmune anemia; membrane protein defects for hereditary spherocytosis; α-and β-chain gene mutations for thalassemia; hemoglobin S polymerization for sickle cell anemia; and oxidative stress for G6PD deficiency, which can cause either intra- or extravascular destruction.•In a patient with jaundice, identifying unconjugated and conjugated hyperbilirubinemia helps limit the differential diagnosis possibilities.•Laboratory results that suggest hemolytic anemia include decreased haptoglobin, increased reticulocytes, and increased lactate dehydrogenase.•The peripheral blood smear is a valuable tool in the diagnosis of hemolytic anemias because many of the diagnoses show abnormal erythrocyte morphology.•The clinical histories and inheritance patterns of hereditary anemias may point toward the correct diagnosis for an anemic patient.•Erythrocyte-intrinsic causes of extravascular hemolysis include abnormalities of enzymes, hemoglobin, and membranes.•G6PD deficiency is an X-linked recessive disorder most prevalent in Sub-Saharan Africa, the Middle East, and South Asia. The most common manifestation is acute hemolytic anemia triggered by food, medication, or infection.•Diagnostic testing for G6PD deficiency should occur several months after an acute hemolytic episode to avoid a false-negative result. •Mechanisms of shortened red cell survival include: (intravascular destruction): mechanical shearing for microangiopathic hemolytic anemia; (extravascular destruction): IgA-mediated opsonization for autoimmune anemia; membrane protein defects for hereditary spherocytosis; α-and β-chain gene mutations for thalassemia; hemoglobin S polymerization for sickle cell anemia; and oxidative stress for G6PD deficiency, which can cause either intra- or extravascular destruction. Mechanisms of shortened red cell survival include: (intravascular destruction): mechanical shearing for microangiopathic hemolytic anemia; (extravascular destruction): IgA-mediated opsonization for autoimmune anemia; membrane protein defects for hereditary spherocytosis; α-and β-chain gene mutations for thalassemia; hemoglobin S polymerization for sickle cell anemia; and oxidative stress for G6PD deficiency, which can cause either intra- or extravascular destruction. •In a patient with jaundice, identifying unconjugated and conjugated hyperbilirubinemia helps limit the differential diagnosis possibilities. In a patient with jaundice, identifying unconjugated and conjugated hyperbilirubinemia helps limit the differential diagnosis possibilities. •Laboratory results that suggest hemolytic anemia include decreased haptoglobin, increased reticulocytes, and increased lactate dehydrogenase. Laboratory results that suggest hemolytic anemia include decreased haptoglobin, increased reticulocytes, and increased lactate dehydrogenase. •The peripheral blood smear is a valuable tool in the diagnosis of hemolytic anemias because many of the diagnoses show abnormal erythrocyte morphology. The peripheral blood smear is a valuable tool in the diagnosis of hemolytic anemias because many of the diagnoses show abnormal erythrocyte morphology. •The clinical histories and inheritance patterns of hereditary anemias may point toward the correct diagnosis for an anemic patient. The clinical histories and inheritance patterns of hereditary anemias may point toward the correct diagnosis for an anemic patient. •Erythrocyte-intrinsic causes of extravascular hemolysis include abnormalities of enzymes, hemoglobin, and membranes. Erythrocyte-intrinsic causes of extravascular hemolysis include abnormalities of enzymes, hemoglobin, and membranes. •G6PD deficiency is an X-linked recessive disorder most prevalent in Sub-Saharan Africa, the Middle East, and South Asia. The most common manifestation is acute hemolytic anemia triggered by food, medication, or infection. G6PD deficiency is an X-linked recessive disorder most prevalent in Sub-Saharan Africa, the Middle East, and South Asia. The most common manifestation is acute hemolytic anemia triggered by food, medication, or infection. •Diagnostic testing for G6PD deficiency should occur several months after an acute hemolytic episode to avoid a false-negative result. Diagnostic testing for G6PD deficiency should occur several months after an acute hemolytic episode to avoid a false-negative result. Funding The authors received no outside funding for the research or preparation of this manuscript. The article processing fee for this article was funded by an Open Access Award given by the Society of ‘67, which supports the mission of the Association for Academic Pathology to produce the next generation of outstanding investigators and educational scholars in the field of pathology. This award helps to promote the publication of high-quality original scholarship in Academic Pathology by authors at an early stage of academic development. Declartion of competing interest The authors have no conflicts of interest to declare. All co-authors have reviewed and approved the manuscript's contents, and there are no financial interests to report.